There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.
Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.
Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.
Roche Holdings AG (RHHBY) announced results from a six-month study combining idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and Ofev.
Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.
Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.
This is a bull market, and some biotech stocks are the real raging bulls—especially when massive drug pipelines are at stake, and landmark FDA approvals shake things up with massive share price momentum. The FDA’s approval just over a week ago of giant Novartis’ new class of cancer drug is a case in point. This was a landmark ruling, and Novartis now holds the status as the first company to win approval for a new class of cancer drug, its CAR-T Kymriah. Nothing shakes up the biotech world like an FDA approval, or even hints that…
Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.
North Korea-related tensions weighed on stocks across the world last week.
Novartis medication marketed as Kymriah treats most common type of childhood cancer, but some fear it could spur wave of highly expensive drugsUS regulators approved the first cancer drug that uses a patient’s own cells to fight cancer. But the drug is priced at $475,000. Oncologists described the drug, made by Novartis and marketed as Kymriah, as revolutionary, but critics worried the first-of-its-kind cancer treatment could usher in a new class of ultra-expensive medications. Continue reading...
Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).
Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.
M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks
Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
Почему стоит обратить внимание на огромные европейские корпорации, такие как Novartis, HSBC, Volkswagen и Unilever.